Haemonetics Raises FY27 Revenue Guidance but Trims Margin Outlook Amid CSL Investment

What happened

Haemonetics reported double-digit organic growth in its fiscal second quarter, prompting management to raise its fiscal 2027 revenue growth outlook, but the company simultaneously lowered its operating margin expansion forecast due to increased investments tied to an expanded relationship with plasma collector CSL. This development comes amid a broader portfolio shift toward Hospital and Plasma segments, with Hospital benefiting from electrophysiology and PFA procedure growth while Plasma navigates the near-term CSL transition. The raised top-line guidance signals stronger-than-expected demand, yet the margin guidance cut reflects management's willingness to sacrifice near-term profitability to secure long-term Plasma volume and customer commitment. Prior disclosures had indicated no North America disposables sales to CSL Plasma in fiscal 2026, so the expanded relationship suggests a potential re-engagement that could stabilize or even grow Plasma revenues in subsequent years. Overall, the news adds mild positive revenue visibility but tempers the earnings outlook, leaving the investment thesis broadly unchanged from a neutral, watchful stance.

Implication

The raised revenue guidance indicates demand resilience and successful Hospital execution, yet the concurrent margin downgrade underscores the cost of rebuilding the CSL Plasma relationship and signals that management prioritizes volume over immediate profitability. Given the company's trailing P/E around 11.7x and a $500 million buyback authorization, any pullback on margin concerns could provide a decent risk-reward if the CSL investment proves value-accretive over the medium term. However, investors should scrutinize the specifics of the expanded CSL relationship—whether it includes longer-term pricing concessions or capacity commitments that could dilute margins beyond the initial investment phase. The master report's monitoring dashboard remains relevant: track Plasma segment revenue and margin trends, cash generation, and management's capital allocation amid ongoing convertible maturities. Until there is clear evidence that CSL volume stabilizes and margins recover, the stock likely remains range-bound, warranting a neutral to cautious stance rather than aggressive accumulation.

Thesis delta

The master report's watch/neutral stance was premised on CSL Plasma transition uncertainty and need for stabilization evidence. Today's raised revenue outlook adds modest confidence that demand trends are improving, particularly in Hospital, but the lowered margin expansion forecast directly contradicts a key profitability assumption. Consequently, the thesis delta is mixed: revenue visibility improves, yet earnings quality and near-term profitability remain under pressure, keeping the overall risk-reward roughly in line with prior expectations.